Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Liposomal Amikacin for Inhalation in Cystic Fibrosis with Pseudomonas Aeruginosa
NCT00777296Phase 2Completed
- Sponsor
- Insmed Incorporated
- Start
- Feb 2007
- Primary completion
- Feb 2008
- Modality
- Small Molecules, Lipid-based Nanoparticles
- Countries
- 7
01
Overview
A Phase 2 trial of amikacin in cystic fibrosis (CF), sponsored by Insmed Incorporated. Started Feb 2007; status: completed.
02
Drugs
amikacin
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT00777296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00777296.